Age, Biography and Wiki
Julie Gerberding was born on 22 August, 1955 in Estelline, South Dakota, United States, is an American physician, educator, infectious disease specialist. Discover Julie Gerberding's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is She in this year and how She spends money? Also learn how She earned most of networth at the age of 69 years old?
| Popular As |
N/A |
| Occupation |
Chief Executive Officer for the Foundation for the National Institutes of Health |
| Age |
69 years old |
| Zodiac Sign |
Leo |
| Born |
22 August, 1955 |
| Birthday |
22 August |
| Birthplace |
Estelline, South Dakota, U.S. |
| Nationality |
United States |
We recommend you to check the complete list of Famous People born on 22 August.
She is a member of famous with the age 69 years old group.
Julie Gerberding Height, Weight & Measurements
At 69 years old, Julie Gerberding height not available right now. We will update Julie Gerberding's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Who Is Julie Gerberding's Husband?
Her husband is David A. Rose
| Family |
| Parents |
Not Available |
| Husband |
David A. Rose |
| Sibling |
Not Available |
| Children |
Not Available |
Julie Gerberding Net Worth
Her net worth has been growing significantly in 2022-2023. So, how much is Julie Gerberding worth at the age of 69 years old? Julie Gerberding’s income source is mostly from being a successful . She is from United States. We have estimated
Julie Gerberding's net worth
, money, salary, income, and assets.
| Net Worth in 2023 |
$1 Million - $5 Million |
| Salary in 2023 |
Under Review |
| Net Worth in 2022 |
Pending |
| Salary in 2022 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
Julie Gerberding Social Network
Timeline
The Obama Administration did not reappoint Gerberding, and she resigned from her post on January 20, 2009.
In late 2009, Gerberding became president of Merck's vaccines division.
Soon after her arrival at the CDC, Gerberding began an overhaul of the agency's organizational structure. On April 21, 2005 Gerberding formally announced the reorganization of CDC to "confront the challenges of 21st-century health threats". This reorganization resulted in the following structure:
In 2005, she was named one of Time magazine's Top 100 Innovators of the Year for her leadership in modernizing the $9 billion agency as it faced unprecedented challenges, including new and emerging infectious diseases and bioterrorism. In 2006, Dr. Gerberding gave the commencement speech at the Harvard School of Public Health. Forbes magazine listed her 32nd among The World's 100 Most Powerful Women in 2007 and 24th in 2008. In addition to serving as a delegate in the World Economic Forum, Gerberding recently received the Surgeon General’s Medallion for actions of exceptional achievement to the cause of public health and medicine. For her contributions to the health field, Accordia Global Health Foundation honored Dr. Gerberding with the Global Health Leadership Award in 2008.
Before becoming CDC Director and ATSDR Administrator, Gerberding was Acting Deputy Director of the National Center for Infectious Diseases (NCID), where she played a major role in leading CDC's response to the anthrax bioterrorism events of 2001. She joined CDC in 1998 as Director of the Division of Healthcare Quality Promotion, NCID, where she developed CDC's patient safety initiatives and other programs to prevent infections, antimicrobial resistance, and medical errors in healthcare settings. Prior to coming to CDC, Gerberding was a faculty member at the University of California at San Francisco (UCSF) and directed the Prevention Epicenter, a multidisciplinary research, training, and clinical service program that focused on preventing infections in patients and their healthcare providers. Gerberding is a Clinical Professor of Medicine (Infectious Diseases) at Emory University and an Associate Professor of Medicine (Infectious Diseases) at UCSF.
In 1998, Gerberding joined the CDC as director of the Division of Healthcare Quality Promotion for the National Center for Infectious Diseases (NCID), where she developed the CDC’s patient safety initiatives and other disease prevention programs. She rose to become the acting deputy director of NCID and helped lead the CDC’s response to the anthrax bioterrorism events of 2001.
Gerberding earned a B.A. magna cum laude in chemistry and biology and an M.D. at Case Western Reserve University in Cleveland, Ohio. Gerberding then completed her internship and residency in internal medicine at UCSF, where she also served as Chief Medical Resident before completing her fellowship in Clinical Pharmacology and Infectious Diseases at UCSF. She earned an M.P.H. degree at the University of California, Berkeley in 1990.
Julie Louise Gerberding (born August 22, 1955) is an American infectious disease expert and the former director of the U.S. Centers for Disease Control and Prevention (CDC) and administrator of the Agency for Toxic Substances and Disease Registry (ATSDR).
